Literature DB >> 23445288

Evaluation of coagulation in dogs with partial or complete extrahepatic biliary tract obstruction by means of thromboelastography.

Philipp D Mayhew1, Michelle R Savigny, Cynthia M Otto, Dorothy Cimino Brown, Marjory B Brooks, Adrienne M Bentley, Jeffrey J Runge, Mary Beth Callan.   

Abstract

OBJECTIVE: To characterize in vitro coagulation status in a cohort of dogs with extrahepatic biliary tract obstruction (EHBO) and to evaluate these patients for hypercoagulability by means of thromboelastography.
DESIGN: Prospective cohort study. Animals-10 dogs with EHBO and 19 healthy control dogs. PROCEDURES: Partial or complete EHBO was confirmed via exploratory celiotomy. Venous blood samples were collected for evaluation of prothrombin time (PT) and activated partial thromboplastin time (APTT); fibrinogen and D-dimer concentrations; protein C and antithrombin activities; and factor VII, VIII, and XI coagulant activities in plasma as well as thromboelastography in whole blood. Thromboelastography variables were measured from the thromboelastography tracing, and a coagulation index was calculated. Thromboelastography results were compared with those of healthy control dogs previously evaluated by the same laboratory.
RESULTS: Hypercoagulability was diagnosed in all dogs with EHBO on the basis of a high coagulation index. Thromboelastography variables, including maximal amplitude, α-angle, and coagulation index, were significantly higher, and K (clot formation time) and R (reaction time) were significantly lower in these dogs than in control dogs. All dogs with EHBO had PT and APTT within respective reference ranges. Plasma D-dimer and fibrinogen concentrations were above reference ranges in 8 and 7 dogs, respectively, and protein C and antithrombin activities were below reference ranges in 3 and 1 dogs, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: In vitro hypercoagulability was commonly detected in dogs with naturally occurring EHBO. The traditional view of EHBO as a disease that causes hypocoagulability may need to be reconsidered.

Entities:  

Mesh:

Year:  2013        PMID: 23445288     DOI: 10.2460/javma.242.6.778

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  6 in total

1.  Thromboelastographic Evaluation of Dogs with Acute Liver Disease.

Authors:  D Kelley; C Lester; S Shaw; A de Laforcade; C R L Webster
Journal:  J Vet Intern Med       Date:  2015 Jul-Aug       Impact factor: 3.333

2.  Thromboelastography in Dogs with Chronic Hepatopathies.

Authors:  W Fry; C Lester; N M Etedali; S Shaw; A DeLaforcade; C R L Webster
Journal:  J Vet Intern Med       Date:  2017-01-18       Impact factor: 3.333

3.  Correlation Between D-Dimer Concentrations and Thromboelastography in Dogs With Critical Illness: A Retrospective, Cross-Sectional Study.

Authors:  Hyun-Jung Han; Jung-Hyun Kim
Journal:  Front Vet Sci       Date:  2022-04-14

4.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1- Defining populations at risk.

Authors:  Armelle deLaforcade; Lenore Bacek; Marie-Claude Blais; Corrin Boyd; Benjamin M Brainard; Daniel L Chan; Stefano Cortellini; Robert Goggs; Guillaume L Hoareau; Amy Koenigshof; Ron Li; Alex Lynch; Alan Ralph; Elizabeth Rozanski; Claire R Sharp
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-05-02

5.  Bile duct obstruction associated with pancreatitis in 46 dogs.

Authors:  Ashley R Wilkinson; Stefanie M DeMonaco; David L Panciera; Cristiane C Otoni; Michael S Leib; Martha M Larson
Journal:  J Vet Intern Med       Date:  2020-08-27       Impact factor: 3.333

6.  Choledochal stenting for treatment of extrahepatic biliary obstruction in cats.

Authors:  Maureen A Griffin; William T N Culp; Michelle A Giuffrida; Laura E Selmic; Jordan C Denitz; James A Perry; Alexander C Schoelkopf; Milan Milovancev; Heidi Phillips; Mandy L Wallace; Michele A Steffey; Ingrid M Balsa; Philipp D Mayhew
Journal:  J Vet Intern Med       Date:  2021-09-29       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.